FENS 2020 | Gut microbiota as a potential therapeutic target in Huntington’s disease

Anthony Hannan, PhD, Florey Institute, University of Melbourne, Melbourne, Australia, outlines the advantage of studying the gut microbiota in Huntington’s disease. In this neurodegenerative disease, it is possible to consider not just symptomatic individuals but individuals who have the gene mutation and don’t yet have symptoms. Therefore, it allows us to do a much cleaner study on the direct effects of the disease on the gut microbiota rather than just indirect effects. Additionally, Prof. Hannan talks on the manipulation of the gut microbiota as a potential therapeutic target. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).